LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magnetic resonance.

Trial Profile

LCZ696 in heart failure patients with reduced ejection fraction and high comorbidity: effect on left ventricular remodeling and fibrosis assessed by novel heart failure biomarkers and cardiac magnetic resonance.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Chronic heart failure
  • Focus Therapeutic Use
  • Acronyms LCZ696-17 Study
  • Most Recent Events

    • 27 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top